Last checked at 11 Dec 2018 07:00
11 December 2018
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Posting of Annual Report and Notice of AGM
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its Annual Report and Accounts for the year ended 31 July 2018 and the Notice of the 2018 Annual General Meeting are now available on the Company's website www.avacta.com.
Copies of the Annual Report and Accounts and the Notice of AGM have been posted to shareholders who have elected to receive them in paper form.
The Annual General Meeting will be held on Monday, 21 January 2018 at 2.00 p.m. at the offices of WG Partners LLP at 85 Gresham Street, London EC2V 7NQ. Shareholders who plan to attend are requested, if possible, to register their attendance by email to investorevents@avacta.com.
- Ends -
For further information from Avacta Group plc, please contact:
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer
| Tel: +44 (0) 844 414 0452 www.avacta.com |
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Sunila de Silva - ECM
WG Partners Nigel Birks / Nigel Barnes David Wilson / Claes Spang
| Tel: +44 (0) 207 220 0500 www.finncap.com
Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217 www.wgpartners.co.uk
|
Turner Pope Investments James Pope / Ben Turner
Zyme Communications (Trade and Regional Media) Katie Odgaard
Yellow Jersey (Financial Media and IR) Sarah Hollins Harriet Jackson | Tel: +44 (0) 203 621 4120www.turnerpope.com
Tel: +44 (0)7787 502 947 www.zymecommunications.com
Tel: +44 (0)7764 947137 Tel: +44 (0)7544 275882 avacta@yellowjerseypr.com |
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts